Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors

Milton Packer, Mihai Gheorghiade, James B. Young, Peter J. Costantini, Kirkwood F. Adams, Robert J. Cody, L. Kent Smith, Lucy Van Voorhees, Lynn A. Gourley, M. King Jolly

Research output: Contribution to journalArticle

641 Citations (Scopus)

Abstract

Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed. Results. Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001 ) and body weight (P<0.001). Conclusions. These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalNew England Journal of Medicine
Volume329
Issue number1
StatePublished - Jul 1 1993

Fingerprint

Digoxin
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Placebos
Diuretics
Systolic Heart Failure
Enalapril
Exercise Tolerance
Captopril
Stroke Volume
Heart Rate
Body Weight
Quality of Life
Confidence Intervals
Exercise

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Packer, M., Gheorghiade, M., Young, J. B., Costantini, P. J., Adams, K. F., Cody, R. J., ... Jolly, M. K. (1993). Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. New England Journal of Medicine, 329(1), 1-7.

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. / Packer, Milton; Gheorghiade, Mihai; Young, James B.; Costantini, Peter J.; Adams, Kirkwood F.; Cody, Robert J.; Smith, L. Kent; Van Voorhees, Lucy; Gourley, Lynn A.; Jolly, M. King.

In: New England Journal of Medicine, Vol. 329, No. 1, 01.07.1993, p. 1-7.

Research output: Contribution to journalArticle

Packer, M, Gheorghiade, M, Young, JB, Costantini, PJ, Adams, KF, Cody, RJ, Smith, LK, Van Voorhees, L, Gourley, LA & Jolly, MK 1993, 'Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors', New England Journal of Medicine, vol. 329, no. 1, pp. 1-7.
Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. New England Journal of Medicine. 1993 Jul 1;329(1):1-7.
Packer, Milton ; Gheorghiade, Mihai ; Young, James B. ; Costantini, Peter J. ; Adams, Kirkwood F. ; Cody, Robert J. ; Smith, L. Kent ; Van Voorhees, Lucy ; Gourley, Lynn A. ; Jolly, M. King. / Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. In: New England Journal of Medicine. 1993 ; Vol. 329, No. 1. pp. 1-7.
@article{b0eb89bd748a4d1da259348110e74290,
title = "Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors",
abstract = "Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed. Results. Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001 ) and body weight (P<0.001). Conclusions. These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.",
author = "Milton Packer and Mihai Gheorghiade and Young, {James B.} and Costantini, {Peter J.} and Adams, {Kirkwood F.} and Cody, {Robert J.} and Smith, {L. Kent} and {Van Voorhees}, Lucy and Gourley, {Lynn A.} and Jolly, {M. King}",
year = "1993",
month = "7",
day = "1",
language = "English (US)",
volume = "329",
pages = "1--7",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "1",

}

TY - JOUR

T1 - Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors

AU - Packer, Milton

AU - Gheorghiade, Mihai

AU - Young, James B.

AU - Costantini, Peter J.

AU - Adams, Kirkwood F.

AU - Cody, Robert J.

AU - Smith, L. Kent

AU - Van Voorhees, Lucy

AU - Gourley, Lynn A.

AU - Jolly, M. King

PY - 1993/7/1

Y1 - 1993/7/1

N2 - Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed. Results. Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001 ) and body weight (P<0.001). Conclusions. These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.

AB - Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class II or III heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed. Results. Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001 ) and body weight (P<0.001). Conclusions. These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0027216221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027216221&partnerID=8YFLogxK

M3 - Article

VL - 329

SP - 1

EP - 7

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 1

ER -